Skip to main content

Market Overview

Morgan Stanley Feels Confidence in Charles River Laboratories Following Solid 4Q13 EPS Report


In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on Charles River Laboratories (NYSE: CRL).

In the report, Morgan Stanley noted, “CRL reported 4Q13 EPS of $0.73 vs. cons/MS at $0.68 with beat driven by below the line items. Specifically, sources of upside vs. MS included sales (+$0.01), net int. (+$0.02), other inc. ($0.01), tax rate (+$0.04) and share count (+$0.01), offset by operating margin (-$0.04).”

Charles River Laboratories closed on Tuesday at $57.99.

Latest Ratings for CRL

Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings


Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Reiteration Analyst Ratings

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at